Merck KGaA is to begin a Phase IIb trial of its investigational drug sprifermin in patients with osteoarthritis (OA) of …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

